Now that India's largest pharmaceutical company is sold to Japan's Daiichi Sankyo for $4.6 billion it is head for much bigger dimensions in pharmaceuticals business. Daiichi Sankyo is already third biggest drug maker and acquiring Ranbaxy to its fold is sure to develop much more a commanding position in the market of pharmaceuticals. There are already positive fluctuations in share market for Ranbaxy and after the deal gets fully settled there are quite chances that it will stablise to the advantage of the community. More importantly significant move on their part is that they are taking it as a mission to produce cheaper and moderately priced drugs for those who can't afford costly medicines. Hopefully they succeed in their mission.